Process development and immunogenicity studies on a serogroup ‘X’ Meningococcal polysaccharide conjugate vaccine
- 1 May 2014
- journal article
- Published by Elsevier in Biologicals
- Vol. 42 (3) , 160-168
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all agesVaccine, 2009
- Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccinesNature Reviews Immunology, 2009
- Investigation of the detoxification mechanism of formaldehyde-treated tetanus toxinVaccine, 2007
- Meningococcal Meningitis: Unprecedented Incidence of Serogroup X--Related Cases in 2006 in NigerClinical Infectious Diseases, 2007
- CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cellsBlood, 2006
- Purification of capsular polysaccharide from Neisseria meningitidis serogroup C by liquid chromatographyJournal of Chromatography B, 2006
- A novel chemistry for conjugating pneumococcal polysaccharides to Luminex microspheresJournal of Immunological Methods, 2006
- Determination of lipid profile in meningococcal polysaccharide using reversed-phase liquid chromatographyJournal of Chromatography B, 2004
- Prospective Study of a Serogroup XNeisseria meningitidisOutbreak in Northern GhanaThe Journal of Infectious Diseases, 2002
- Preclinical Evaluation of a Novel Group B Meningococcal Conjugate Vaccine that Elicits Bactericidal Activity in both Mice and Nonhuman PrimatesThe Journal of Infectious Diseases, 1997